[COPD - An Underestimated Disease]. - Publication

Publication

[COPD - An Underestimated Disease].

Journal Paper/Review - Jun 1, 2023

Leuppi Joerg Daniel, Bridevaux Pierre-Olivier, Charbonnier Florian, Clarenbach Christian F, Duchna Hans-Werner, Fellrath Jean-Marc, Gianella Pietro, Jochmann Anja, Kern Lukas, Nikolay Pavlov, Rothe Thomas, Steurer-Stey Claudia, von Garnier Christophe

Citation

Leuppi J, Bridevaux P, Charbonnier F, Clarenbach C, Duchna H, Fellrath J, Gianella P, Jochmann A, Kern L, Nikolay P, Rothe T, Steurer-Stey C, von Garnier C. [COPD - An Underestimated Disease]. Praxis (Bern 1994) 2023; 112:403-412.

Type

Journal Paper/Review (Deutsch)

Journal

Praxis (Bern 1994) 2023; 112

Publication Date

Jun 1, 2023

Issn Print

1661-8157

Pages

403-412

Brief description/objective

COPD - An Underestimated Disease Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition with a complex clinical picture. The diagnosis is not easy to make because COPD can develop insidiously and remain unnoticed for a long time. Therefore, general practitioners play a central role in the early detection of the disease. Suspected COPD can be confirmed by special examinations in collaboration with pulmonologists. The new GOLD guideline defines three COPD risk groups (A-B-E) which should guide the personalized treatment concept. A short- or long-acting bronchodilator (SAMA/SABA or LAMA/LABA) is recommended for group A, and a dual long-acting bronchodilator therapy (LABA+LAMA) is recommended for group B and E. In case of blood eosinophilia (≥300 cells/µl) and/or recent hospitalization for COPD exacerbation, triple therapy (LABA+LAMA+ICS) is recommended. General practitioners are important in implementing non-pharmacological measures (smoking cessation, regular exercise, vaccinations, patient selfmanagement education). However, this also underlines the high demands of the implementation of the GOLD guideline in daily practice.